Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 240-245-2 | CAS number: 16090-02-1
Rat oral LD50: 7562 mg/kg bwRat inhalation LD50 > 1895 mg/m3Rat dermal LD50 > 2000 mg/kg bw
Several acute toxicity studies are available: all were performed on rats and they were conducted following test procedures similar to those outlined into the OECD guideline 401. The lots tested were different, with different concentration percentages of the substance. Nevertheless, all the test clearly indicated that the substance is not harmful and thus the lowest LD50 identified has been chosen for the Risk Assessment: 7562 mg/kg bw (Ciba-Geigy Ltd., 1975).
A good GLP Klimish 1 study for acute dermal toxicity is reported (Ciba-Geigy Ltd., 1990). It was performed just at 2000 mg/Kg bw and no systemic signs were observed in the animals during the entire observation period (RCC, Research & Consulting Company AG., 1990).
Because of the physical state and the trade forms, inhalation is not an appropriate route of exposure. Acute toxicity results for the other two exposure routes indicate no concern therefore no testing was performed. One test is available on an analogous substance, performed at the maximum allowed concentration of 1890 mg/m3: no effects were observed. The analogous substance, part of the Stilbene Fluorescent Withening Agents, group 3, is the acid form of the disulphonated derivative dihydroxyethyl derivative (Justification for Read Across is reported in the Category Justification Report attached to the Section 13 of the dossier).
As a conclusion, it can be stated that the substance is not acutely toxic for all the three exposure ways.
According to the CLP Regulation (EC 1272/2008), 3.1 Acute toxicity section, substances can be allocated to one of four toxicity categories based on acute toxicity by the oral, dermal or inhalation route according to the numeric criteria. Acute toxicity values are expressed as (approximate) LD50 (oral, dermal) or LC50 (inhalation) values or as acute toxicity estimates (ATE).
The oral LD50 value was established to be ca 7562 mg/kg body weight, therefore the test substance is out of any classification limit for acute oral toxicity (oral acute toxicity category 4: 300 < ATE ≤ 2000 mg/kg bw).
The dermal LD50 value was established to exceed 2000 mg/kg body weight, which exceeded the highest CLP classification limit (dermal acute toxicity category 4: 1000 < ATE ≤ 2000 mg/kg bw).
The inhalation LC50 value was established to be greater than 1895 mg/m3. For powder the limit for classification is ATE > 5 mg/l i. e. 5000 mg/m3.
Since no effect was observed at the tested concentration and this was the maximum reachable concentration in the test condition, it is assumed that the substance is not classified for inhalation acute toxicity.
In conclusion, the available experimental data are adequate for classification and labelling and the test substance is non classified for oral and dermal acute toxicity, according to the CLP Regulation (EC 1272/2008).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again